WEDNESDAY, MARCH 29

7:00am-7:00pm Conference Registration Open

PRE-CONFERENCE AKI SYMPOSIUM (CME Available)

(see page 3 for elective symposium and workshop fees)

Changing Paradigms in Acute Kidney Injury: From Mechanisms to Management

Presented by UAB/UCSD O'Brien Center for AKI Research

CRRT Conference registration is NOT required for this elective symposium. See page 4 for details.

Note	7:55 am	Opening Remarks - Ravindra Mehta, MD
8:00-8:20 8:20-8:40 8:20-8:40 8:40-9:00 9:00-9:20 10:00-9:00 9:20-9:40 9:20-9:40 9:20-9:40 10:00-10:15 Coffee Break PLENARY 2 Of Mice and Men: Harmonizing Human and Animal AKI Co-Chairs: Prabhleen Singh and Paul Sanders Mechanisms of Phagocytosis and Cell Clearance: Implications in Inflammation Sanja Arandjelovic 10:35-10:55 Mechanisms of Phagocytosis and Cell Clearance: Implications in Inflammation Sanja Arandjelovic 10:35-10:55 Metabolism and Nutrition in Sepsis - Sarah Huen 10:55-11:15 Mitochondrial Therapy in AKI - Amandeep Bajwa 11:35-11:35 11:55-12:15 Discussion Lunch Hosted by Conference PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Mathlieu LeGrand 11:5-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 13:51-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi Discussion 1:00-00-00-00-00-00-00-00-00-00-00-00-00-	PLENARY 1	,
8:20-8:40 8:40-9:00 9:40-9:20 9:20-9:40 Cilia and PCP in AKI and Kidney Repair - Zheng Dong 9:40-10:00 10:00-10:15 Coffee Break PLENARY 2 Of Mice and Men: Harmonizing Human and Animal AKI Co-Chairs: Prabliken Singh and Paul Sanders Mechanisms of Phagocytosis and Cell Clearance: Implications in Inflammation Sanja Arandjelovic 10:35-10:55 Metabolism and Nutrition in Sepsis - Sarah Huen 11:55-11:35 Mitochondrial Therapy in AKI - Sherry Mansour 11:35-11:55 11:35-12:15 Mitochondrial Therapy in AKI - Sherry Mansour 11:45-11:35 Mitochondrial Therapy in AKI - Sherry Mansour 11:45-12:15 Mitochondrial Therapy in AKI - Sherry Mansour 11:55-12:15 Mitochondrial Therapy in AKI - Sherry Mansour 11:55-13:5 Moved Therapeutics in AKI and Critical Illness - Orson Moe 11:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 11:55-3:30 Coffee Break Co-Chairs: Marlies Ostermann and Eddie Siew 11:55-3:4 Mitochondrial Tubular Cell Dysfunction in SA-AKI Co-Chairs: Marlies Ostermann and Eddie Siew 11:55-3:4 Mitochondrial Tubular Cell Dysfunction Predicts MAKE - Alex Bullen 11:50-4:10 Mitochondrial Tubular Cell Dysfunction Predicts MAKE - Alex Bullen 11:50-5:10 Mitochondrial Tubular Cell Dysfunction Predicts MAKE - Alex B		
8:40-9:00 9:00-9:20 9:20-9:40 9:20-9:40 9:20-9:40 9:20-9:40 10:00-10:15 Coffice Break PLENARY 2 Of Mice and Men: Harmonizing Human and Animal AKI Co-Chairs: Prabhleen Singh and Paul Sanders 10:15-10:35 Mechanisms of Phagocytosis and Cell Clearance: Implications in Inflammation Sanja Arandjelovic 10:35-10:55 Metabolism and Nutrition in Sepsis - Sarah Huen Mitochondrial Therapy in AKI - Sherry Mansour Kidney Microphysiological Models for Nephrotoxicity Assessment - Sejoong Kim Discussion 11:35-11:35 Discussion 12:15-1:15pm Lunch Hosted by Conference PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Mathieu LeGrand 1:15-1:25 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Mathieu LeGrand 1:15-1:25 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Mathieu LeGrand 1:15-1:25 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Mathieu LeGrand 1:15-1:25 Bone Dysregulation in AKI and Critical Illness - Orson Moe Harnessing Tubular Transport for Reducing Drug Rephrotoxicity - Pranav Garimella Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi Sympathetic Nerve Activation in AKI - Kent Doi Discussion Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion		
9:00-9:20 9:20-9:40 9:20-9		•
9:20-9:40 9:40-10:00 10:00-10:15 Coffee Break PLENARY 2 Of Mice and Men: Harmonizing Human and Animal AKI Co-Chairs: Prabbleen Singh and Paul Sanders Nechanisms of Phagocytosis and Cell Clearance: Implications in Inflammation Sanja Arandjelovic 10:35-10:35 Metabolism and Nutrition in Sepsis - Sarah Huen Mitochondrial Therapy in AKI - Amandeep Bajiwa Angiopoietins as Biomarkers in AKI - Sherry Mansour 11:35-11:35 Ridney Microphysiological Models for Nephrotoxicity Assessment - Sejoong Kim Discussion Lunch Hosted by Conference PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Matthieu LeGrand 1:15-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi Sympathetic Nerve Activation in AKI - Kent Doi Discussion 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen Nephrotoxin Stewardship - Sandra Kane Gill RIPC: Does it Work? - Alex Zarbock The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion		
9:40-10:00 10:00-10:15 Coffee Break PLENARY 2 Of Mice and Men: Harmonizing Human and Animal AKI Co-Chairs: Prabhleen Singh and Paul Sanders 10:15-10:35 Mechanisms of Phagocytosis and Cell Clearance: Implications in Inflammation Sanja Arandjelovic Metabolism and Nutrition in Sepsis - Sarah Huen Mitochondrial Therapy in AKI - Amandeep Bajwa 11:15-11:35 Angiopoietins as Biomarkers in AKI - Sherry Mansour Kidney Microphysiological Models for Nephrotoxicity Assessment - Sejoong Kim Discussion Lunch Hosted by Conference PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Matthieu LeGrand 1:15-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella 1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi Discussion Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon Tubular Dysfunction Predicts MAKE - Alex Bullen Nephrotoxin Stewardship - Sandra Kane Gill RIPC: Does it Work? - Alex Zarbock The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion		
PLENARY 2 Of Mice and Men: Harmonizing Human and Animal AKI Co-Chains: Prabhleen Singh and Paul Sanders Mechanisms of Phagocytosis and Cell Clearance: Implications in Inflammation Sanja Arandjelovic Metabolism and Nutrition in Sepsis - Sarah Huen Mitochondrial Therapy in AKI - Amandeep Bajwa 11:15-11:135 Angiopoietins as Biomarkers in AKI - Sherry Mansour Kidney Microphysiological Models for Nephrotoxicity Assessment - Sejoong Kim Discussion Lunch Hosted by Conference PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Matthieu LeGrand 1:15-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella 1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi Discussion Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen Nephrotoxin Stewardship - Sandra Kane Gill RIPC: Does it Work? - Alex Zarbock The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion Discussion		
PLENARY 2 Of Mice and Men: Harmonizing Human and Animal AKI Co-Chairs: Prabhleen Singh and Paul Sanders Mechanisms of Phagocytosis and Cell Clearance: Implications in Inflammation Sanja Arandjelovic Metabolism and Nutrition in Sepsis - Sarah Huen Mitochondrial Therapy in AKI - Amandeep Bajwa Angiopoietins as Biomarkers in AKI - Sherry Mansour Kidney Microphysiological Models for Nephrotoxicity Assessment - Sejoong Kim Discussion Lunch Hosted by Conference PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Mathieu LeGrand 1:15-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella 1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi Discussion 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen Nephrotoxin Stewardship - Sandra Kane Gill RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion		
10:15-10:35 Mechanisms of Phagocytosis and Cell Clearance: Implications in Inflammation Sanja Arandjelovic 10:35-10:55 Metabolism and Nutrition in Sepsis - Sarah Huen 10:55-11:15 Mitochondrial Therapy in AKI - Amandeep Bajwa 11:15-11:35 Angiopoietins as Biomarkers in AKI - Sherry Mansour 11:35-11:55 Kidney Microphysiological Models for Nephrotoxicity Assessment - Sejoong Kim 11:55-12:15 Discussion 12:15-1:15pm Lunch Hosted by Conference PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Matthieu LeGrand 1:15-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella 1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno 1:15-2:35 RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 1:235-2:55 Sympathetic Nerve Activation in AKI - Kent Doi 1:255-3:15 Discussion 1:30-3:50 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 1:30-3:50 Subphenotypes of AKI in Children - Shina Menon 1:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 1:4:04-3:0 Nephrotoxin Stewardship - Sandra Kane Gill 1:4:30-4:50 RIPC: Does it Work? - Alex Zarbock 1:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 1:05:10-5:30 Discussion	10:00-10:15	
Sanja Arandjelovic 10:35-10:55 Metabolism and Nutrition in Sepsis - Sarah Huen Mitochondrial Therapy in AKI - Amandeep Bajwa 11:15-11:35 Angiopoietins as Biomarkers in AKI - Sherry Mansour Kidney Microphysiological Models for Nephrotoxicity Assessment - Sejoong Kim Discussion Lunch Hosted by Conference PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Matthieu LeGrand 1:15-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella 1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi Sympathetic Nerve Activation in AKI - Kent Doi Discussion 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion	PLENARY 2	
10:55-11:15 Mitochondrial Therapy in AKI - Amandeep Bajwa 11:15-11:35 Angiopoietins as Biomarkers in AKI - Sherry Mansour 11:35-11:55 Kidney Microphysiological Models for Nephrotoxicity Assessment - Sejoong Kim 11:55-12:15 Discussion 12:15-1:15pm Lunch Hosted by Conference PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Matthieu LeGrand 1:15-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella 1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno 2:15-2:35 RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi 2:55-3:15 Discussion 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion	10:15-10:35	
11:15-11:35	10:35-10:55	Metabolism and Nutrition in Sepsis - Sarah Huen
11:35-11:55 11:55-12:15 12:15-1:15pm Lunch Hosted by Conference PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Matthieu LeGrand 1:15-1:35 1:35-12:55 1:35-12:55 1:35-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi Discussion Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion	10:55-11:15	Mitochondrial Therapy in AKI - Amandeep Bajwa
Discussion Lunch Hosted by Conference PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Matthieu LeGrand 1:15-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella 1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno 2:15-2:35 RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi Discussion 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion		•
PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Matthieu LeGrand 1:15-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella 1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno 2:15-2:35 RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi Discussion 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion		
PLENARY 3 Bench to Bedside: Translating Discoveries to Clinical Care Co-Chairs: Kathleen Liu and Matthieu LeGrand 1:15-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella 1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi Sympathetic Nerve Activation in AKI - Kent Doi Discussion 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion		
Co-Chairs: Kathleen Liu and Matthieu LeGrand 1:15-1:35 Bone Dysregulation in AKI and Critical Illness - Orson Moe 1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella 1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno 2:15-2:35 RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi Discussion 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion	12:15-1:15pm	Lunch Hosted by Conference
1:35-1:55 Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella 1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno 2:15-2:35 RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi 2:55-3:15 Discussion 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion	PLENARY 3	
1:55-2:15 Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno 2:15-2:35 RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi 2:55-3:15 Discussion 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion	1:15-1:35	Bone Dysregulation in AKI and Critical Illness - Orson Moe
2:15-2:35 RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi 2:55-3:15 Discussion 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion	1:35-1:55	Harnessing Tubular Transport for Reducing Drug Nephrotoxicity - Pranav Garimella
Vincenzo Cantaluppi 2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi 2:55-3:15 Discussion 3:15-3:30 Coffee Break Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion	1:55-2:15	Novel Therapeutics in AKI: Can Hydrogels Work in Humans? - Danielle Soranno
2:35-2:55 Sympathetic Nerve Activation in AKI - Kent Doi 2:55-3:15 Discussion 3:15-3:30 Coffee Break Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion	2:15-2:35	RCA to Limit Inflammation and Mitochondrial Tubular Cell Dysfunction in SA-AKI
2:55-3:15 3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion		
3:15-3:30 Coffee Break PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion		· ·
PLENARY 4 Controversies in AKI Co-Chairs: Marlies Ostermann and Eddie Siew 3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion		
3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion	3:15-3:30	Coffee Break
3:30-3:50 Subphenotypes of AKI in Children - Shina Menon 3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion	PLENARY 4	
3:50-4:10 Tubular Dysfunction Predicts MAKE - Alex Bullen 4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion	2.20 2.50	
4:10-4:30 Nephrotoxin Stewardship - Sandra Kane Gill 4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion		
4:30-4:50 RIPC: Does it Work? - Alex Zarbock 4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion		•
4:50-5:10 The Economics of AKI: What Makes it so Costly? - Glenn Chertow 5:10-5:30 Discussion		······································
5:10-5:30 Discussion		RIPU: Does if Work? - Alex Zarbock
J.JO Aujourii	4:50-5:10	The Economics of AKI: What Makes it so Costly? - Glenn Chertow
	4:50-5:10 5:10-5:30	The Economics of AKI: What Makes it so Costly? - Glenn Chertow Discussion

Wednesday Evening Reception & Poster Review - For All Conference Attendees

5:30-7:00pm